Want to join the conversation?
$JNJ said its Janssen Research & Development unit has submitted a supplemental New Drug Application for ibrutinib to the US FDA for the treatment of patients with marginal zone lymphoma who require systemic therapy. Marginal zone lymphoma affects the white blood cells. The filing is based on data from the Phase 2 PCYC-1121 trial.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.